Patents
Sitemap › A61 - Medical or veterinary science; Hygiene › A61K - Preparations for medical, dental, or toilet purposes › A61K 47 - Medicinal preparations characterised by the non-active ingredients used, e.g. carriers, inert additives
Patents for A61K 47 - Medicinal preparations characterised by the non-active ingredients used, e.g. carriers, inert additives (171,128)
04/2010
04/21/2010CN101695494A Composition of cefpriome sulfate and sodium citrate
04/21/2010CN101695493A Composition of cefmetazole acid and sodium citrate
04/21/2010CN101695489A Aztreonam composition, powder injection and preparation method thereof
04/21/2010CN101695488A Compound articaine freeze-drying preparation for injection and preparation method thereof
04/21/2010CN101695487A Polyenoic ethyl ester emulsion of high-purity EPA-E and DHA-E
04/21/2010CN101695483A Independently controllable contraceptive transdermal patch containing progestogen and estrogen and preparation method thereof
04/21/2010CN101695482A Glipizide orally disintegrating tablet and preparation process thereof
04/21/2010CN101695481A Mitiglinide calcium dispersible tablet and preparation method thereof
04/21/2010CN101695480A Olopatadine hydrochloride dispersible tablets, preparation method thereof and quality control method thereof
04/21/2010CN101695479A Instant pirarubicin freeze-dried powder injection and preparation method thereof
04/21/2010CN101695478A Tamsulosin hydrochloride sustained-release pellets and preparation method thereof
04/21/2010CN101695477A Method for preparing potato starch medicament carrier microspheres
04/21/2010CN101695476A Method for preparing medical nanoparticles
04/21/2010CN101695475A Ozagrel sodium injection and preparation method thereof
04/21/2010CN101695474A Pharmaceutical composition of vinflunine which is intended for parenteral administration preparation method thereof and use of same
04/21/2010CN101695473A Use and preparation method of vaginal thermosensitive gel
04/21/2010CN101695374A Composition comprising alkaline sphingomyelinase for use as a dietetic preparation, food supplement or pharmaceutical product
04/21/2010CN101390848B Medicine composition azithromycin enteric-coated capsules
04/21/2010CN101249085B Bilobalide A, B compound injection and preparation method and application thereof
04/21/2010CN101240026B Conjugate constructed from normal tridecyl and RGD peptide, and its synthesis and application in medicine
04/21/2010CN101229224B Chinese traditional medicine ointment preparation for curing vitligo and preparing method thereof
04/21/2010CN101172161B Water-soluble polymers decorated G-CSF conjugates
04/21/2010CN101167719B Gallo catechin and gallate microcapsule granule and preparation technique thereof
04/21/2010CN101167710B Chloromycetin eyedrops with long quality guaranteed period and preparation method thereof
04/21/2010CN101129358B Moguisteine sustained-release tablet and method of preparing the same
04/21/2010CN101066455B Medicine carrying aquogel matrix for preparing plaster and its preparation process
04/21/2010CN101062950B Polyethylene glycol modified thymus peptide 1 derivative
04/21/2010CN101040957B Medicine for treating skin diseases such as eczema and dermatitis and the method for preparing the same
04/20/2010USRE41252 Peptidyl prodrugs and linkers and stabilizers useful therefor
04/20/2010US7700775 Drug delivery
04/20/2010US7700722 Polyoxyethylene glycol-modified tumor necrosis factor for higher concentrations, decreased viscosity, and improved stability; for treatment of inflammation
04/20/2010US7700659 Implantable devices formed of non-fouling methacrylate or acrylate polymers
04/20/2010US7700588 Pharmaceutical compositions comprising midazolam in a high concentration
04/20/2010US7700582 Pharmaceutical formulation
04/20/2010US7700579 Process for the preparation of piroxicam: b-cyclodextrin inclusion compounds
04/20/2010US7700569 Single- or double-stranded stabilized DNA contains nonmethylated octameric CG motif of the sequence AACGTTAT (nucleotides 9-16 of SEQ ID NO: 9); phosphorothioate oligonucleotides; nuclease inhibitors; immunostimulants; nontoxic; anticarcinogenic agents; intratumoral administration; nervous systems
04/20/2010US7700561 Abuse-resistant amphetamine prodrugs
04/20/2010US7700559 Gonadotropin releasing hormone analogues conjugates with steroid hormones
04/20/2010US7700554 Compositions for modulating blood-brain barrier transport
04/20/2010US7700551 Hydrolysable polymeric FMOC-linker
04/20/2010US7700550 Telavancin or its hydrochloride salt for infection, including MRSA infections; reduced tissue accumulation and/or nephrotoxicity
04/20/2010US7700314 Method for producing polyol-IFN-β conjugate
04/20/2010US7700297 Artery- and vein-specific proteins and uses therefor
04/20/2010US7700141 Composition
04/20/2010US7700127 Method and compositions for preparing and delivering rumen protected lipids, other nutrients and medicaments
04/20/2010US7700117 Camp factor of Streptococcus uberis
04/20/2010US7700116 Method of inducing an immune response in a host by administering immunogenic compositions comprising UV-irradiated, psoralen-inactivated, desialated human immunodeficiency virus (HIV) particles devoid of CD55 and CD59 in the viral membrane
04/20/2010US7700087 Compounds and methods to inhibit or augment an inflammatory response
04/20/2010US7700085 Administering an agent which inhibits binding of advanced glycation endproducts to any of their receptors; wound healing
04/20/2010US7699987 Stabilized formulation
04/20/2010US7699889 Poly(ester amide) block copolymers
04/20/2010US7699832 Medical device having a surface including a biologically active agent therein, and methods
04/20/2010US7699609 Dispensing apparatus and cartridge with deformable tip
04/20/2010CA2563185C Sustained release formulations of a peptide or protein and a purified gallic acid ester
04/20/2010CA2448829C Preparation for the removal of abnormal keratinous material
04/20/2010CA2447926C Single-daily-dose antidiabetic oral pharmaceutical form comprising a biguanide and at least another active principle
04/20/2010CA2437697C Parasiticidal compositions and methods of use
04/20/2010CA2433335C Particles for inhalation having sustained release properties
04/20/2010CA2432178C Sustained release pharmaceutical dosage forms with minimized ph dependent dissolution profiles
04/20/2010CA2426764C Nateglinide-containing hydrophilic pharmaceutical preparation
04/20/2010CA2425338C Compositions comprising modafinil compounds
04/20/2010CA2400172C Nanocapsule encapsulation system and method
04/20/2010CA2388240C Phenoxy carboxylic acid compounds and compositions for delivering active agents
04/20/2010CA2386826C Use of l-carnitine and its alkanoyl derivatives as osmotic agents in solutions for peritoneal dialysis
04/20/2010CA2379727C Use of propionic bacteria for producing propionic acid and/or propionates in the colon
04/20/2010CA2368334C Acidic gelled aqueous cosmetic compositions comprising oil-containing biliquid foam dispersion
04/20/2010CA2361587C Methods and compositions to enhance white blood cell count
04/20/2010CA2359573C Conjugates of colony stimulating factors for targeting and imaging infection and inflammation
04/20/2010CA2332701C Medium and matrix for long-term proliferation of cells
04/20/2010CA2319680C Compounds and compositions for delivering active agents
04/20/2010CA2299429C New lipopolyamines,their preparation and the use thereof
04/20/2010CA2279331C Compounds and compositions for delivering active agents
04/20/2010CA2278345C Monohydric alcohol derived urethanes and their use in cosmetic formulations
04/20/2010CA2180872C Composition containing nucleic acids, preparation and uses
04/20/2010CA2179779C Vaccine compositions comprising oil in water emulsions with tocopherol and squalene
04/20/2010CA1341603C Acidic polysaccharide esters and process for their preparation
04/15/2010WO2010042742A2 Chimeric therapeutics, compositions, and methods for using same
04/15/2010WO2010042638A2 Hpma - docetaxel or gemcitabine conjugates and uses therefore
04/15/2010WO2010042633A2 Naringenin complexes and methods of use thereof
04/15/2010WO2010042553A1 Aerosol fluoroquinolone formulations for improved pharmacokinetics
04/15/2010WO2010042145A1 Polymer conjugates of glp-2-like peptides
04/15/2010WO2010041722A2 Pharmaceutical composition
04/15/2010WO2010041684A1 Tacrolimus preparation for external applications
04/15/2010WO2010041141A2 Oil-based foamable carriers and formulations
04/15/2010WO2010041138A2 Complex between human insulin and an amphiphilic polymer, and use of said complex for preparing a quick human insulin formulation
04/15/2010WO2010041119A1 Polysaccharides containing carboxyl functional groups substituted by a hydrophobic alcohol derivative
04/15/2010WO2010041051A1 Pharmaceutical formulation 514
04/15/2010WO2010040772A2 Targeting construct comprising anti-polymer antibody and liposomes or microvesicles binding to the same
04/15/2010WO2010040562A1 A polymer-free hydrogel
04/15/2010WO2010040464A1 Isosorbide-derivatives
04/15/2010WO2010040312A1 Composite material and its prepration, using in tumor therapy and aititumor medicine
04/15/2010WO2010040232A1 Use of scyllo-inositols for the treatment of macular degeneration-related disorders
04/15/2010WO2010040204A1 Detection of granulosa-cell tumors
04/15/2010WO2010040188A1 Biodegradable polymer - bioactive moiety conjugates
04/15/2010WO2010040187A1 Polymer-bioactive agent conjugates
04/15/2010WO2010040173A1 A method of delivering functional agents across the blood-brain barrier
04/15/2010WO2010013823A3 Pharmaceutical composition
04/15/2010WO2010009449A3 Extended release pharmaceutical formulations of s-adenosylmethionine
04/15/2010WO2010003668A3 Treatment of solid tumors with tissue inhibitors of metalloproteinases (timps)
04/15/2010WO2009152347A3 Crystalline forms of zotepine hydrochloride
1 ... 504 505 506 507 508 509 510 511 512 513 514 515 516 517 518 519 520 521 522 523 524 ... 1712